Skip to main content

01.06.2022 | Original Article

Twist1 Promoter Methylation Regulates the Proliferation and Apoptosis of Acute Myeloid Leukemia Cells via PI3K/AKT Pathway

verfasst von: Aihong Gong, Xiaojia Wang, Xuewei Wang, Ying Zhao, Yanan Cui

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Twist-related protein 1 (Twist1) is a widely recognized oncogene in acute myeloid leukemia (AML), and its promoter methylation is related with the progression of solid tumors. However, the association between Twist1 promoter methylation and AML has not been well studied. Twist1 mRNA expression was detected using quantitative real-time polymerase chain reaction (qRT-PCR). The protein levels of Twist1 and phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signal were measured via western blotting. Methylation-specific PCR was performed to detect the methylation status of Twist1 promoter. CCK-8 assay and flow cytometry were used to reveal cellular biological effects. Twist1 expression and promoter methylation level were significantly upregulated in AML tissues and cell lines and were further downregulated in demethylating agent 5′-azacitidine (5-Aza)-treated cells. Ectopic expression of Twist1 increased AML cell viability, while reducing apoptosis, and attenuated the effects of 5-Aza on the proliferation and apoptosis. We also found that the PI3K/AKT signaling pathway was positively regulated by Twist1. Our findings revealed that Twist1 accelerates the tumorigenesis of AML cells by promoting its promoter methylation via the activation of PI3K/AKT signaling pathway.
Literatur
1.
Zurück zum Zitat De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6(7):e441CrossRef De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6(7):e441CrossRef
2.
Zurück zum Zitat Pelcovits A, Niroula R (2020) Acute myeloid leukemia: a review. R I Med J (2013) 103(3):38–40 Pelcovits A, Niroula R (2020) Acute myeloid leukemia: a review. R I Med J (2013) 103(3):38–40
3.
Zurück zum Zitat Kassim AA, Savani BN (2017) Hematopoietic stem cell transplantation for acute myeloid leukemia: a review. Hematol Oncol Stem Cell Ther 10(4):245–251CrossRef Kassim AA, Savani BN (2017) Hematopoietic stem cell transplantation for acute myeloid leukemia: a review. Hematol Oncol Stem Cell Ther 10(4):245–251CrossRef
4.
Zurück zum Zitat Takami A (2018) Hematopoietic stem cell transplantation for acute myeloid leukemia. Int J Hematol 107(5):513–518CrossRef Takami A (2018) Hematopoietic stem cell transplantation for acute myeloid leukemia. Int J Hematol 107(5):513–518CrossRef
5.
Zurück zum Zitat Medeiros BC (2018) Is there a standard of care for relapsed AML? Best Pract Res Clin Haematol 31(4):384–386CrossRef Medeiros BC (2018) Is there a standard of care for relapsed AML? Best Pract Res Clin Haematol 31(4):384–386CrossRef
6.
Zurück zum Zitat Zhang G et al (2019) High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol 98(2):519–525CrossRef Zhang G et al (2019) High ETS2 expression predicts poor prognosis in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol 98(2):519–525CrossRef
7.
Zurück zum Zitat Zhao Z et al (2017) Multiple biological functions of Twist1 in various cancers. Oncotarget 8(12):20380–20393CrossRef Zhao Z et al (2017) Multiple biological functions of Twist1 in various cancers. Oncotarget 8(12):20380–20393CrossRef
8.
Zurück zum Zitat Liu X et al (2018) Niche TWIST1 is critical for maintaining normal hematopoiesis and impeding leukemia progression. Haematologica 103(12):1969–1979CrossRef Liu X et al (2018) Niche TWIST1 is critical for maintaining normal hematopoiesis and impeding leukemia progression. Haematologica 103(12):1969–1979CrossRef
9.
Zurück zum Zitat Dong CY et al (2014) Twist-1, a novel regulator of hematopoietic stem cell self-renewal and myeloid lineage development. Stem Cells 32(12):3173–3182CrossRef Dong CY et al (2014) Twist-1, a novel regulator of hematopoietic stem cell self-renewal and myeloid lineage development. Stem Cells 32(12):3173–3182CrossRef
10.
Zurück zum Zitat Chen CC et al (2015) Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia. Blood Cancer J 5:e339CrossRef Chen CC et al (2015) Favorable clinical outcome and unique characteristics in association with Twist1 overexpression in de novo acute myeloid leukemia. Blood Cancer J 5:e339CrossRef
11.
Zurück zum Zitat Xu J et al (2016) DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1. J Hematol Oncol 9(1):106CrossRef Xu J et al (2016) DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1. J Hematol Oncol 9(1):106CrossRef
12.
Zurück zum Zitat Li H et al (2020) Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine. Haematologica 105(10):e502CrossRef Li H et al (2020) Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine. Haematologica 105(10):e502CrossRef
13.
Zurück zum Zitat Zhu QQ et al (2016) The role of TWIST1 in epithelial-mesenchymal transition and cancers. Tumour Biol 37(1):185–197CrossRef Zhu QQ et al (2016) The role of TWIST1 in epithelial-mesenchymal transition and cancers. Tumour Biol 37(1):185–197CrossRef
14.
Zurück zum Zitat Alaaeldin R et al (2021) Modulation of apoptosis and epithelial-mesenchymal transition E-cadherin/TGF-beta/Snail/TWIST pathways by a new ciprofloxacin chalcone in breast cancer cells. Anticancer Res 41(5):2383–2395CrossRef Alaaeldin R et al (2021) Modulation of apoptosis and epithelial-mesenchymal transition E-cadherin/TGF-beta/Snail/TWIST pathways by a new ciprofloxacin chalcone in breast cancer cells. Anticancer Res 41(5):2383–2395CrossRef
15.
Zurück zum Zitat Gort EH et al (2008) Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomark Prev 17(12):3325–3330CrossRef Gort EH et al (2008) Methylation of the TWIST1 promoter, TWIST1 mRNA levels, and immunohistochemical expression of TWIST1 in breast cancer. Cancer Epidemiol Biomark Prev 17(12):3325–3330CrossRef
16.
Zurück zum Zitat Ruppenthal RD et al (2011) TWIST1 promoter methylation in primary colorectal carcinoma. Pathol Oncol Res 17(4):867–872CrossRef Ruppenthal RD et al (2011) TWIST1 promoter methylation in primary colorectal carcinoma. Pathol Oncol Res 17(4):867–872CrossRef
17.
Zurück zum Zitat Kwon MJ et al (2013) TWIST1 promoter methylation is associated with prognosis in tonsillar squamous cell carcinoma. Hum Pathol 44(9):1722–1729CrossRef Kwon MJ et al (2013) TWIST1 promoter methylation is associated with prognosis in tonsillar squamous cell carcinoma. Hum Pathol 44(9):1722–1729CrossRef
18.
Zurück zum Zitat Galvan JA et al (2015) TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget 6(2):874–885CrossRef Galvan JA et al (2015) TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget 6(2):874–885CrossRef
19.
Zurück zum Zitat Wang XX et al (2020) TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer. Exp Cell Res 386(1):111713CrossRef Wang XX et al (2020) TWIST1 transcriptionally regulates glycolytic genes to promote the Warburg metabolism in pancreatic cancer. Exp Cell Res 386(1):111713CrossRef
20.
Zurück zum Zitat Xu Y et al (2017) Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene 36(8):1157–1166CrossRef Xu Y et al (2017) Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene 36(8):1157–1166CrossRef
21.
Zurück zum Zitat Liu YQ et al (2020) MiR-526b suppresses cell proliferation, cell invasion and epithelial-mesenchymal transition in breast cancer by targeting Twist1. Eur Rev Med Pharmacol Sci 24(6):3113–3121 Liu YQ et al (2020) MiR-526b suppresses cell proliferation, cell invasion and epithelial-mesenchymal transition in breast cancer by targeting Twist1. Eur Rev Med Pharmacol Sci 24(6):3113–3121
22.
Zurück zum Zitat Zhao C et al (2020) Increased NFATC4 correlates With poor prognosis of AML through recruiting regulatory T cells. Front Genet 11:573124CrossRef Zhao C et al (2020) Increased NFATC4 correlates With poor prognosis of AML through recruiting regulatory T cells. Front Genet 11:573124CrossRef
23.
Zurück zum Zitat Lao TD, Nguyen TN, Le TAH (2021) Promoter hypermethylation of tumor suppressor genes located on short arm of the chromosome 3 as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Diagnostics (Basel) 11(8):1404CrossRef Lao TD, Nguyen TN, Le TAH (2021) Promoter hypermethylation of tumor suppressor genes located on short arm of the chromosome 3 as potential biomarker for the diagnosis of nasopharyngeal carcinoma. Diagnostics (Basel) 11(8):1404CrossRef
24.
Zurück zum Zitat Fain JS et al (2021) Transcriptional overlap links DNA hypomethylation with DNA hypermethylation at adjacent promoters in cancer. Sci Rep 11(1):17346CrossRef Fain JS et al (2021) Transcriptional overlap links DNA hypomethylation with DNA hypermethylation at adjacent promoters in cancer. Sci Rep 11(1):17346CrossRef
25.
Zurück zum Zitat Lee E et al (2021) recent clinical update of acute myeloid leukemia: focus on epigenetic therapies. J Korean Med Sci 36(13):e85CrossRef Lee E et al (2021) recent clinical update of acute myeloid leukemia: focus on epigenetic therapies. J Korean Med Sci 36(13):e85CrossRef
26.
Zurück zum Zitat Samimi H et al (2021) DNA methylation analysis improves the prognostication of acute myeloid leukemia. EJHaem 2(2):211–218CrossRef Samimi H et al (2021) DNA methylation analysis improves the prognostication of acute myeloid leukemia. EJHaem 2(2):211–218CrossRef
27.
Zurück zum Zitat Fan Z et al (2020) Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription. Neoplasia 22(11):617–629CrossRef Fan Z et al (2020) Targeting methyltransferase PRMT5 retards the carcinogenesis and metastasis of HNSCC via epigenetically inhibiting Twist1 transcription. Neoplasia 22(11):617–629CrossRef
28.
Zurück zum Zitat Wu X et al (2021) The miR-302s/367 cluster inhibits the proliferation and apoptosis in sheep fetal fibroblasts via the cell cycle and PI3K-Akt pathways. Mamm Genome 32(3):183–194CrossRef Wu X et al (2021) The miR-302s/367 cluster inhibits the proliferation and apoptosis in sheep fetal fibroblasts via the cell cycle and PI3K-Akt pathways. Mamm Genome 32(3):183–194CrossRef
29.
Zurück zum Zitat Chen Q, Wang M, Shen C (2020) Bauerane induces S-phase cell cycle arrest, apoptosis, and inhibition of proliferation of A549 human lung cancer cells through the phosphoinositide 3-kinase (PI3K)/AKT and signal transducer and activator of transcription 3 (STAT3) signaling pathway. Med Sci Monit 26:e919558 Chen Q, Wang M, Shen C (2020) Bauerane induces S-phase cell cycle arrest, apoptosis, and inhibition of proliferation of A549 human lung cancer cells through the phosphoinositide 3-kinase (PI3K)/AKT and signal transducer and activator of transcription 3 (STAT3) signaling pathway. Med Sci Monit 26:e919558
30.
Zurück zum Zitat Gao H et al (2021) Yiqi-Huoxue granule promotes angiogenesis of ischemic myocardium through miR-126/PI3K/Akt axis in endothelial cells. Phytomedicine 92:153713CrossRef Gao H et al (2021) Yiqi-Huoxue granule promotes angiogenesis of ischemic myocardium through miR-126/PI3K/Akt axis in endothelial cells. Phytomedicine 92:153713CrossRef
31.
Zurück zum Zitat Huang J et al (2021) MicroRNA93 knockdown inhibits acute myeloid leukemia cell growth via inactivating the PI3K/AKT pathway by upregulating DAB2. Int J Oncol 59(4):1–14CrossRef Huang J et al (2021) MicroRNA93 knockdown inhibits acute myeloid leukemia cell growth via inactivating the PI3K/AKT pathway by upregulating DAB2. Int J Oncol 59(4):1–14CrossRef
32.
Zurück zum Zitat Shi M et al (2021) LncRNA-SNHG16 promotes proliferation and migration of acute myeloid leukemia cells via PTEN/PI3K/AKT axis through suppressing CELF2 protein. J Biosci 46:1–13CrossRef Shi M et al (2021) LncRNA-SNHG16 promotes proliferation and migration of acute myeloid leukemia cells via PTEN/PI3K/AKT axis through suppressing CELF2 protein. J Biosci 46:1–13CrossRef
33.
Zurück zum Zitat Zhou C et al (2021) GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia. Cell Death Dis 12(3):231CrossRef Zhou C et al (2021) GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia. Cell Death Dis 12(3):231CrossRef
34.
Zurück zum Zitat Yuan R, Chang J, He J (2020) Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway. Cell Mol Biol (Noisy-le-grand) 66(6):81–85CrossRef Yuan R, Chang J, He J (2020) Effects of Twist1 on drug resistance of chronic myeloid leukemia cells through the PI3K/AKT signaling pathway. Cell Mol Biol (Noisy-le-grand) 66(6):81–85CrossRef
Metadaten
Titel
Twist1 Promoter Methylation Regulates the Proliferation and Apoptosis of Acute Myeloid Leukemia Cells via PI3K/AKT Pathway
verfasst von
Aihong Gong
Xiaojia Wang
Xuewei Wang
Ying Zhao
Yanan Cui
Publikationsdatum
01.06.2022
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2023
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-022-01540-2

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.